Literature DB >> 16323213

Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients.

Giovanni Raimondo1, Maurizia R Brunetto, Patrizia Pontisso, Antonina Smedile, Anna Maria Maina, Carlo Saitta, Giovanni Squadrito, Natascia Tono.   

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfection is often associated with severe forms of liver disease. However, comprehensive studies are lacking, and scant information is available regarding the virological behavior over time in coinfected patients. This study enrolled 133 untreated HBV/HCV-positive patients (male/female = 102/31; median age 51 years [range: 22-83 years]) who were longitudinally followed up for 1 year with bimonthly evaluation of HBV/HCV viremia levels and liver biochemistry. Thirty of these patients had triple infection with hepatitis Delta virus (HDV), while 103 patients were HDV-negative. In the HDV-negative group, active infection with both HBV and HCV was revealed in 24 cases, inactive infection by both viruses was seen in 15 cases, active HBV/inactive HCV was seen in 15 cases, and inactive HBV/active HCV was seen in 49 cases. However, 32 subjects (31%) presented dynamic virological profiles characterized by fluctuation of HBV and/or HCV viremia levels that at different time points were over or under the cutoff limits. Consequently, a correct diagnosis could be performed in these subjects only by serially repeating the virological tests 1 year apart. Similarly, 15 of the 30 HDV-positive subjects showed active HBV and/or HCV infection, with fluctuating virological patterns in 8 cases. In conclusion, this study showed that the virological patterns in HBV/HCV coinfection are widely divergent and have dynamic profiles. A careful longitudinal evaluation of the viremia levels of both viruses is essential for making a correct diagnosis and tailoring the appropriate therapeutic schedule in coinfected patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16323213     DOI: 10.1002/hep.20944

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  40 in total

1.  Current concept in the pathophysiology of hepatitis delta infection.

Authors:  Grazia Anna Niro; Antonina Smedile
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

Review 2.  Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection.

Authors:  Chun-Jen Liu; Pei-Jer Chen
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 3.  Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.

Authors:  Nicole D Ferrante; Vincent Lo Re
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.071

4.  Parasite interactions in natural populations: insights from longitudinal data.

Authors:  S Telfer; R Birtles; M Bennett; X Lambin; S Paterson; M Begon
Journal:  Parasitology       Date:  2008-05-12       Impact factor: 3.234

5.  Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients.

Authors:  Robert L Kruse; Jennifer R Kramer; Gia L Tyson; Zhigang Duan; Liang Chen; Hashem B El-Serag; Fasiha Kanwal
Journal:  Hepatology       Date:  2014-10-29       Impact factor: 17.425

6.  Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection.

Authors:  Xiaoming Cheng; Takuro Uchida; Yuchen Xia; Regina Umarova; Chun-Jen Liu; Pei-Jer Chen; Anuj Gaggar; Vithika Suri; Marcus M Mücke; Johannes Vermehren; Stefan Zeuzem; Yuji Teraoka; Mitsutaka Osawa; Hiroshi Aikata; Keiji Tsuji; Nami Mori; Shuhei Hige; Yoshiyasu Karino; Michio Imamura; Kazuaki Chayama; T Jake Liang
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 7.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

Review 8.  MiR-122 in hepatitis B virus and hepatitis C virus dual infection.

Authors:  Kyoungsub Song; Chang Han; Srikanta Dash; Luis A Balart; Tong Wu
Journal:  World J Hepatol       Date:  2015-03-27

9.  Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals.

Authors:  Saverio G Parisi; Samantha Andreis; Monica Basso; Silvia Cavinato; Renzo Scaggiante; Marzia Franzetti; Massimo Andreoni; Giorgio Palù; Anna Maria Cattelan
Journal:  Med Microbiol Immunol       Date:  2017-09-01       Impact factor: 3.402

Review 10.  Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead.

Authors:  Heiner Wedemeyer; Michael P Manns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.